Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646907 | 0.86 | IDO1 (0.42) | CYP3A4IDO1AGXTPNMTMAOA | |
| SCHEMBL25671333 | 0.85 | CYP3A4 (0.55) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL18596694 | 0.81 | CYP3A4 (0.55) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL14814484 | 0.81 | CYP3A4 (0.50) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL27900596 | 0.81 | CYP3A4 (0.50) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL14814486 | 0.81 | CYP3A4 (0.50) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL17069262 | 0.79 | IDO1 (0.52) | CYP3A4IDO1AGXTPNMTTSHR | |
| SCHEMBL27813296 | 0.79 | CYP3A4 (0.47) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL10226540 | 0.78 | TP53 (0.39) | IDO1AGXTTSHRTAAR1KDM4E | |
| SCHEMBL8750484 | 0.78 | IDO1 (0.60) | IDO1MAOBMAOATAAR1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023115203-A1 | OXER1 ANTAGONISTS AND USES THEREOF | FAIRHAVEN PHARMACEUTICALS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| US-9730913-B2 | High affinity beta lactamase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730913-B2 | High affinity beta lactamase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-15 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8853237-B2 | Naphthyridinone analogs as mGluR5 positive allosteric modulators | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140256778-A1 | HIGH AFFINITY BETA LACTAMASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256778-A1 | HIGH AFFINITY BETA LACTAMASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | CYP3A4 4792/4885IDO1 1084/4885AGXT 3914/4885 |
| US-20140256778-A1 | HIGH AFFINITY BETA LACTAMASE INHIBITORS | ALPI, GUSB, LCT | CYP3A4 671/4885IDO1 1196/4885AGXT 564/4885 |
| US-20230174506-A1 | (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME | NAAA, PAM, AANAT | CYP3A4 310/4885IDO1 199/4885AGXT 533/4885 |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | CYP3A4 3185/4885IDO1 1914/4885AGXT 1789/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | CYP3A4 3185/4885IDO1 1914/4885AGXT 1789/4885 |
| US-20120172391-A1 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | CYP3A4 3758/4885IDO1 2330/4885AGXT 3029/4885 |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | CYP3A4 4808/4885IDO1 2887/4885AGXT 3081/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | CYP3A4 899/4885IDO1 1035/4885AGXT 3389/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | CYP3A4 175/4885IDO1 1238/4885AGXT 926/4885 |
| US-20150259331-A1 | PROTOZOAN PARASITE GROWTH INHIBITORS | TPP1, MKI67, PIGO | CYP3A4 3246/4885IDO1 584/4885AGXT 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.